Screener
Odyssey Therapeutics ODTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Odyssey Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Odyssey Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335822
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from the issuance of convertible preferred stock, net of issuance costs | — | 118,752 |
| Net cash provided by financing activities | 292,644 | 118,923 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 128 | 392 |
| Increase in cash, cash equivalents and restricted cash | 40,587 | 103,865 |
| Cash, cash equivalents and restricted cash, beginning of period | 44,897 | 62,346 |
| Cash, cash equivalents and restricted cash, end of period | $85,484 | $166,211 |
| Cash and cash equivalents, end of period | $82,031 | $163,001 |
| Restricted cash, included in other non-current assets, end of period | 3,453 | 3,210 |
Item 1. Financial Statements.
FAQ
- What is Odyssey Therapeutics's net change in cash?
- Odyssey Therapeutics (ODTX) reported net change in cash of $46.31M in Q2 2026.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Odyssey Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude